Dianthus Therapeutics
DNTH
241 hedge funds and large institutions have $5.36B invested in Dianthus Therapeutics in 2026 Q1 according to their latest regulatory filings, with 98 funds opening new positions, 83 increasing their positions, 54 reducing their positions, and 19 closing their positions.
416% more first-time investments, than exits
New positions opened: 98 | Existing positions closed: 19
165% more capital invested
Capital invested by funds: $2.02B → $5.36B (+$3.34B)
100% more funds holding in top 10
Funds holding in top 10: 8 → 16 (+8)
54% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 54
46% more funds holding
Funds holding: 165 → 241 (+76)
30.04% more ownership
Funds ownership: 114.56% → 144.59% (+30%)
12% less call options, than puts
Call options by funds: $19.7M | Put options by funds: $22.3M
Top Buyers
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$122M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$77.4M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$74.8M |
| 4 |
BlackRock
New York
|
+$73M |
| 5 |
FAM
Fred Alger Management
New York
|
+$65.3M |
Top Sellers
| 1 |
Marshall Wace
London,
United Kingdom
|
-$38.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$30.3M |
| 3 |
TLP
Tri Locum Partners
New York
|
-$27.6M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$27.2M |
| 5 |
Millennium Management
New York
|
-$23.5M |
DNTH Hedge Fund Activity: Q1 2026 in Review
241 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q1 2026, worth a combined $5.36B — up 165% from $2.02B a quarter earlier.
Buyers outnumbered sellers: 98 funds opened new DNTH positions and 19 closed out — a net gain of 79 holders — while 83 added to existing stakes and 54 trimmed.
The largest buyer was Avidity Partners Management, adding an estimated $122M. The largest seller was Marshall Wace, cutting an estimated $38.6M.
- 241 institutional investors held Dianthus Therapeutics (DNTH) as of Q1 2026, up from 165 in Q4 2025.
- Funds reported $5.36B of Dianthus Therapeutics stock for Q1 2026, up 165% quarter-over-quarter.
- 98 funds opened new Dianthus Therapeutics positions in Q1 2026 and 19 closed out, a net change of +79 holders.
- The largest Dianthus Therapeutics buyer in Q1 2026 was Avidity Partners Management, an estimated $122M added.
- The largest Dianthus Therapeutics seller in Q1 2026 was Marshall Wace, an estimated $38.6M sold.
Based on aggregated 13F filings for Q1 2026.